Search

Search results

717 results found

Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.

Thaçi, Diamant, Ron Vender, Menno A de Rie, Curdin Conrad, David M Pariser, Bruce Strober, Veerle Vanvoorden, et al. 2023. “Safety and Efficacy of Bimekizumab through 2 Years in Patients With Moderate-to-Severe Plaque Psoriasis: Longer-Term Results from the BE SURE Randomized Controlled Trial and the Open-Label Extension from the BE BRIGHT Trial.”. The British Journal of Dermatology 188 (1): 22-31.

Hanna Wang

Hanna is an undergraduate student in Brown University’s 8-year Program in Liberal Medication (PLME) studying Health and Human Biology. In the lab, she is currently researching the impact of social determinants of health on T2D treatment and epigenetic mechanisms of intergenerational diabetes...